Lonza

1H13: Lonza reported growth of approximately 10%, with Pharma & Biotech segment sales of CHF 609 million.
 
Comments: In the Manufacturing segment, several segments experienced growth, including microbial and mammalian technology offerings, and integrated ADC offerings, as well as new contracts for small molecule products. Custom Development growth was attributed to the mammalian business and expanded microbial capabilities, as well as cell therapy process development services. Bioscience Solutions growth was driven by the progressing long-term Sartorius collaboration and Endotoxin sales, offset by research products facing challenging market environment and competition in Europe and the U.S. Specialty ingredients market sales were CHF 1.1 billion and include Consumer Care, Agro Ingredients, Water Treatment, Wood Protection, and Industrial Solutions. At the end of September Lonza reduced its overall headcount by 744 positions.